Cargando…

Tetraspanins: Novel Molecular Regulators of Gastric Cancer

Gastric cancer is the fourth and fifth most common cancer worldwide in men and women, respectively. However, patients with an advanced stage of gastric cancer still have a poor prognosis and low overall survival rate. The tetraspanins belong to a protein superfamily with four hydrophobic transmembra...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yue, Cai, Sicheng, Shen, Jian, Peng, Huiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250138/
https://www.ncbi.nlm.nih.gov/pubmed/34222025
http://dx.doi.org/10.3389/fonc.2021.702510
_version_ 1783717026754199552
author Deng, Yue
Cai, Sicheng
Shen, Jian
Peng, Huiming
author_facet Deng, Yue
Cai, Sicheng
Shen, Jian
Peng, Huiming
author_sort Deng, Yue
collection PubMed
description Gastric cancer is the fourth and fifth most common cancer worldwide in men and women, respectively. However, patients with an advanced stage of gastric cancer still have a poor prognosis and low overall survival rate. The tetraspanins belong to a protein superfamily with four hydrophobic transmembrane domains and 33 mammalian tetraspanins are ubiquitously distributed in various cells and tissues. They interact with other membrane proteins to form tetraspanin-enriched microdomains and serve a variety of functions including cell adhesion, invasion, motility, cell fusion, virus infection, and signal transduction. In this review, we summarize multiple utilities of tetraspanins in the progression of gastric cancer and the underlying molecular mechanisms. In general, the expression of TSPAN8, CD151, TSPAN1, and TSPAN4 is increased in gastric cancer tissues and enhance the proliferation and invasion of gastric cancer cells, while CD81, CD82, TSPAN5, TSPAN9, and TSPAN21 are downregulated and suppress gastric cancer cell growth. In terms of cell motility regulation, CD9, CD63 and CD82 are metastasis suppressors and the expression level is inversely associated with lymph node metastasis. We also review the clinicopathological significance of tetraspanins in gastric cancer including therapeutic targets, the development of drug resistance and prognosis prediction. Finally, we discuss the potential clinical value and current limitations of tetraspanins in gastric cancer treatments, and provide some guidance for future research.
format Online
Article
Text
id pubmed-8250138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82501382021-07-03 Tetraspanins: Novel Molecular Regulators of Gastric Cancer Deng, Yue Cai, Sicheng Shen, Jian Peng, Huiming Front Oncol Oncology Gastric cancer is the fourth and fifth most common cancer worldwide in men and women, respectively. However, patients with an advanced stage of gastric cancer still have a poor prognosis and low overall survival rate. The tetraspanins belong to a protein superfamily with four hydrophobic transmembrane domains and 33 mammalian tetraspanins are ubiquitously distributed in various cells and tissues. They interact with other membrane proteins to form tetraspanin-enriched microdomains and serve a variety of functions including cell adhesion, invasion, motility, cell fusion, virus infection, and signal transduction. In this review, we summarize multiple utilities of tetraspanins in the progression of gastric cancer and the underlying molecular mechanisms. In general, the expression of TSPAN8, CD151, TSPAN1, and TSPAN4 is increased in gastric cancer tissues and enhance the proliferation and invasion of gastric cancer cells, while CD81, CD82, TSPAN5, TSPAN9, and TSPAN21 are downregulated and suppress gastric cancer cell growth. In terms of cell motility regulation, CD9, CD63 and CD82 are metastasis suppressors and the expression level is inversely associated with lymph node metastasis. We also review the clinicopathological significance of tetraspanins in gastric cancer including therapeutic targets, the development of drug resistance and prognosis prediction. Finally, we discuss the potential clinical value and current limitations of tetraspanins in gastric cancer treatments, and provide some guidance for future research. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8250138/ /pubmed/34222025 http://dx.doi.org/10.3389/fonc.2021.702510 Text en Copyright © 2021 Deng, Cai, Shen and Peng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Deng, Yue
Cai, Sicheng
Shen, Jian
Peng, Huiming
Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title_full Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title_fullStr Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title_full_unstemmed Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title_short Tetraspanins: Novel Molecular Regulators of Gastric Cancer
title_sort tetraspanins: novel molecular regulators of gastric cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250138/
https://www.ncbi.nlm.nih.gov/pubmed/34222025
http://dx.doi.org/10.3389/fonc.2021.702510
work_keys_str_mv AT dengyue tetraspaninsnovelmolecularregulatorsofgastriccancer
AT caisicheng tetraspaninsnovelmolecularregulatorsofgastriccancer
AT shenjian tetraspaninsnovelmolecularregulatorsofgastriccancer
AT penghuiming tetraspaninsnovelmolecularregulatorsofgastriccancer